Fulgent Genetics Q1 2024 Earnings Report $18.34 -0.41 (-2.19%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Fulgent Genetics EPS ResultsActual EPS-$0.38Consensus EPS -$0.58Beat/MissBeat by +$0.20One Year Ago EPSN/AFulgent Genetics Revenue ResultsActual Revenue$64.49 millionExpected Revenue$65.74 millionBeat/MissMissed by -$1.25 millionYoY Revenue GrowthN/AFulgent Genetics Announcement DetailsQuarterQ1 2024Date5/3/2024TimeN/AConference Call ResourcesSlide DeckPress ReleaseFLGT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Fulgent Genetics Earnings HeadlinesWith 54% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backingDecember 21 at 5:48 PM | uk.finance.yahoo.comFulgent Genetics: A Value Stock With Caveats (Rating Downgrade)December 19 at 4:57 AM | seekingalpha.comDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."December 21, 2024 | Banyan Hill Publishing (Ad)Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right NowNovember 20, 2024 | msn.comFulgent Genetics price target lowered to $22 from $26 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comSee More Fulgent Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulgent Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulgent Genetics and other key companies, straight to your email. Email Address About Fulgent GeneticsFulgent Genetics (NASDAQ:FLGT), together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.View Fulgent Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
